TissueGene, Inc. Announces Special Protocol Assessment (SPA) Agreement with the Food and Drug Administration (FDA) for its Phase 3 Clinical Trial of Invossa™ for Patients Suffering from Osteoarthritis of the Knee May 15, 2015
TissueGene, Inc. Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee May 11, 2015
TissueGene Receives Recommendations from FDA on Pathway to Phase 3 Trial of TG-C for Treatment of Osteoarthritis of the Knee Nov 17, 2014
TissueGene Completes Enrollment in U.S. Phase II Study of TG-C in Patients with Knee Osteoarthritis Nov 14, 2012
TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee May 19, 2011